nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—ADRA2A—epilepsy syndrome	0.151	0.471	CbGaD
Zuclopenthixol—HTR2A—epilepsy syndrome	0.0887	0.276	CbGaD
Zuclopenthixol—CYP2D6—epilepsy syndrome	0.0811	0.253	CbGaD
Zuclopenthixol—Amoxapine—Diazepam—epilepsy syndrome	0.0508	0.142	CrCrCtD
Zuclopenthixol—Loxapine—Clobazam—epilepsy syndrome	0.0434	0.121	CrCrCtD
Zuclopenthixol—Clozapine—Clonazepam—epilepsy syndrome	0.0408	0.114	CrCrCtD
Zuclopenthixol—Loxapine—Diazepam—epilepsy syndrome	0.0404	0.113	CrCrCtD
Zuclopenthixol—Clozapine—Clobazam—epilepsy syndrome	0.0373	0.104	CrCrCtD
Zuclopenthixol—Clozapine—Diazepam—epilepsy syndrome	0.0347	0.0968	CrCrCtD
Zuclopenthixol—Chlorprothixene—Midazolam—epilepsy syndrome	0.0307	0.0857	CrCrCtD
Zuclopenthixol—Chlorpromazine—Clobazam—epilepsy syndrome	0.0278	0.0775	CrCrCtD
Zuclopenthixol—Chlorprothixene—Diazepam—epilepsy syndrome	0.0274	0.0764	CrCrCtD
Zuclopenthixol—Prochlorperazine—Clobazam—epilepsy syndrome	0.025	0.0696	CrCrCtD
Zuclopenthixol—HTR2A—phrenic nerve—epilepsy syndrome	0.0049	0.0956	CbGeAlD
Zuclopenthixol—DRD1—telencephalic ventricle—epilepsy syndrome	0.00267	0.052	CbGeAlD
Zuclopenthixol—HTR6—ganglion—epilepsy syndrome	0.00223	0.0435	CbGeAlD
Zuclopenthixol—HTR2A—locus ceruleus—epilepsy syndrome	0.00219	0.0427	CbGeAlD
Zuclopenthixol—DRD5—ganglion—epilepsy syndrome	0.00217	0.0423	CbGeAlD
Zuclopenthixol—HTR2A—cerebellar cortex—epilepsy syndrome	0.00179	0.0348	CbGeAlD
Zuclopenthixol—HTR2A—vagus nerve—epilepsy syndrome	0.00168	0.0327	CbGeAlD
Zuclopenthixol—DRD1—ganglion—epilepsy syndrome	0.00166	0.0323	CbGeAlD
Zuclopenthixol—DRD2—telencephalic ventricle—epilepsy syndrome	0.00157	0.0307	CbGeAlD
Zuclopenthixol—HTR2A—pons—epilepsy syndrome	0.00126	0.0246	CbGeAlD
Zuclopenthixol—HTR2A—autonomic nervous system—epilepsy syndrome	0.00116	0.0227	CbGeAlD
Zuclopenthixol—HTR2A—telencephalic ventricle—epilepsy syndrome	0.00104	0.0202	CbGeAlD
Zuclopenthixol—DRD2—ganglion—epilepsy syndrome	0.00098	0.0191	CbGeAlD
Zuclopenthixol—HTR6—forebrain—epilepsy syndrome	0.000936	0.0182	CbGeAlD
Zuclopenthixol—DRD5—forebrain—epilepsy syndrome	0.000911	0.0178	CbGeAlD
Zuclopenthixol—HTR6—telencephalon—epilepsy syndrome	0.000861	0.0168	CbGeAlD
Zuclopenthixol—DRD5—telencephalon—epilepsy syndrome	0.000838	0.0163	CbGeAlD
Zuclopenthixol—ADRA1A—hindbrain—epilepsy syndrome	0.000759	0.0148	CbGeAlD
Zuclopenthixol—DRD2—hindbrain—epilepsy syndrome	0.000744	0.0145	CbGeAlD
Zuclopenthixol—DRD1—brainstem—epilepsy syndrome	0.000721	0.0141	CbGeAlD
Zuclopenthixol—DRD1—forebrain—epilepsy syndrome	0.000696	0.0136	CbGeAlD
Zuclopenthixol—HTR2A—ganglion—epilepsy syndrome	0.000647	0.0126	CbGeAlD
Zuclopenthixol—DRD1—telencephalon—epilepsy syndrome	0.00064	0.0125	CbGeAlD
Zuclopenthixol—HTR6—head—epilepsy syndrome	0.000536	0.0104	CbGeAlD
Zuclopenthixol—DRD5—head—epilepsy syndrome	0.000522	0.0102	CbGeAlD
Zuclopenthixol—HTR6—nervous system—epilepsy syndrome	0.000508	0.0099	CbGeAlD
Zuclopenthixol—DRD5—nervous system—epilepsy syndrome	0.000495	0.00964	CbGeAlD
Zuclopenthixol—HTR2A—hindbrain—epilepsy syndrome	0.00049	0.00956	CbGeAlD
Zuclopenthixol—HTR6—central nervous system—epilepsy syndrome	0.000489	0.00953	CbGeAlD
Zuclopenthixol—DRD5—central nervous system—epilepsy syndrome	0.000476	0.00928	CbGeAlD
Zuclopenthixol—DRD1—midbrain—epilepsy syndrome	0.00046	0.00896	CbGeAlD
Zuclopenthixol—CYP2D6—hindbrain—epilepsy syndrome	0.000447	0.00871	CbGeAlD
Zuclopenthixol—ADRA1A—brainstem—epilepsy syndrome	0.000435	0.00847	CbGeAlD
Zuclopenthixol—DRD2—brainstem—epilepsy syndrome	0.000426	0.00831	CbGeAlD
Zuclopenthixol—ADRA1A—forebrain—epilepsy syndrome	0.00042	0.00818	CbGeAlD
Zuclopenthixol—DRD2—forebrain—epilepsy syndrome	0.000411	0.00802	CbGeAlD
Zuclopenthixol—DRD1—head—epilepsy syndrome	0.000399	0.00777	CbGeAlD
Zuclopenthixol—HTR6—brain—epilepsy syndrome	0.000388	0.00757	CbGeAlD
Zuclopenthixol—ADRA1A—telencephalon—epilepsy syndrome	0.000386	0.00752	CbGeAlD
Zuclopenthixol—DRD2—telencephalon—epilepsy syndrome	0.000378	0.00737	CbGeAlD
Zuclopenthixol—DRD5—brain—epilepsy syndrome	0.000378	0.00737	CbGeAlD
Zuclopenthixol—DRD1—nervous system—epilepsy syndrome	0.000378	0.00737	CbGeAlD
Zuclopenthixol—DRD1—central nervous system—epilepsy syndrome	0.000364	0.00709	CbGeAlD
Zuclopenthixol—HRH1—forebrain—epilepsy syndrome	0.000325	0.00633	CbGeAlD
Zuclopenthixol—ADRA2A—forebrain—epilepsy syndrome	0.000319	0.00622	CbGeAlD
Zuclopenthixol—HRH1—telencephalon—epilepsy syndrome	0.000299	0.00582	CbGeAlD
Zuclopenthixol—ADRA2A—telencephalon—epilepsy syndrome	0.000293	0.00572	CbGeAlD
Zuclopenthixol—DRD1—brain—epilepsy syndrome	0.000289	0.00563	CbGeAlD
Zuclopenthixol—HTR2A—brainstem—epilepsy syndrome	0.000281	0.00548	CbGeAlD
Zuclopenthixol—DRD2—midbrain—epilepsy syndrome	0.000272	0.00529	CbGeAlD
Zuclopenthixol—HTR2A—forebrain—epilepsy syndrome	0.000271	0.00529	CbGeAlD
Zuclopenthixol—CYP2D6—brainstem—epilepsy syndrome	0.000256	0.00499	CbGeAlD
Zuclopenthixol—HTR2A—telencephalon—epilepsy syndrome	0.000249	0.00486	CbGeAlD
Zuclopenthixol—CYP2D6—forebrain—epilepsy syndrome	0.000247	0.00482	CbGeAlD
Zuclopenthixol—ADRA1A—head—epilepsy syndrome	0.00024	0.00468	CbGeAlD
Zuclopenthixol—DRD2—head—epilepsy syndrome	0.000235	0.00459	CbGeAlD
Zuclopenthixol—ADRA2A—medulla oblongata—epilepsy syndrome	0.000231	0.00449	CbGeAlD
Zuclopenthixol—ADRA1A—nervous system—epilepsy syndrome	0.000228	0.00444	CbGeAlD
Zuclopenthixol—CYP2D6—telencephalon—epilepsy syndrome	0.000227	0.00443	CbGeAlD
Zuclopenthixol—DRD2—nervous system—epilepsy syndrome	0.000223	0.00435	CbGeAlD
Zuclopenthixol—ADRA1A—central nervous system—epilepsy syndrome	0.000219	0.00427	CbGeAlD
Zuclopenthixol—DRD2—central nervous system—epilepsy syndrome	0.000215	0.00419	CbGeAlD
Zuclopenthixol—ADRA1A—cerebellum—epilepsy syndrome	0.000214	0.00418	CbGeAlD
Zuclopenthixol—ADRA2A—midbrain—epilepsy syndrome	0.000211	0.00411	CbGeAlD
Zuclopenthixol—DRD2—cerebellum—epilepsy syndrome	0.00021	0.00409	CbGeAlD
Zuclopenthixol—ADRA2A—spinal cord—epilepsy syndrome	0.000206	0.00401	CbGeAlD
Zuclopenthixol—HTR2A—medulla oblongata—epilepsy syndrome	0.000196	0.00382	CbGeAlD
Zuclopenthixol—HRH1—head—epilepsy syndrome	0.000186	0.00362	CbGeAlD
Zuclopenthixol—ADRA2A—head—epilepsy syndrome	0.000183	0.00356	CbGeAlD
Zuclopenthixol—Flupentixol—CHRM1—epilepsy syndrome	0.000182	0.0445	CrCbGaD
Zuclopenthixol—HTR2A—midbrain—epilepsy syndrome	0.000179	0.00349	CbGeAlD
Zuclopenthixol—HRH1—nervous system—epilepsy syndrome	0.000176	0.00344	CbGeAlD
Zuclopenthixol—HTR2A—spinal cord—epilepsy syndrome	0.000175	0.00341	CbGeAlD
Zuclopenthixol—ADRA1A—brain—epilepsy syndrome	0.000174	0.00339	CbGeAlD
Zuclopenthixol—ADRA2A—nervous system—epilepsy syndrome	0.000173	0.00338	CbGeAlD
Zuclopenthixol—DRD2—brain—epilepsy syndrome	0.000171	0.00333	CbGeAlD
Zuclopenthixol—HRH1—central nervous system—epilepsy syndrome	0.00017	0.00331	CbGeAlD
Zuclopenthixol—ADRA2A—central nervous system—epilepsy syndrome	0.000167	0.00325	CbGeAlD
Zuclopenthixol—ADRA2A—cerebellum—epilepsy syndrome	0.000163	0.00318	CbGeAlD
Zuclopenthixol—HTR2A—head—epilepsy syndrome	0.000155	0.00303	CbGeAlD
Zuclopenthixol—HTR2A—nervous system—epilepsy syndrome	0.000147	0.00287	CbGeAlD
Zuclopenthixol—HTR2A—central nervous system—epilepsy syndrome	0.000142	0.00276	CbGeAlD
Zuclopenthixol—CYP2D6—head—epilepsy syndrome	0.000142	0.00276	CbGeAlD
Zuclopenthixol—HTR2A—cerebellum—epilepsy syndrome	0.000139	0.0027	CbGeAlD
Zuclopenthixol—HRH1—brain—epilepsy syndrome	0.000135	0.00263	CbGeAlD
Zuclopenthixol—CYP2D6—nervous system—epilepsy syndrome	0.000134	0.00261	CbGeAlD
Zuclopenthixol—ADRA2A—brain—epilepsy syndrome	0.000132	0.00258	CbGeAlD
Zuclopenthixol—CYP2D6—central nervous system—epilepsy syndrome	0.000129	0.00252	CbGeAlD
Zuclopenthixol—CYP2D6—cerebellum—epilepsy syndrome	0.000126	0.00246	CbGeAlD
Zuclopenthixol—HTR2A—brain—epilepsy syndrome	0.000113	0.00219	CbGeAlD
Zuclopenthixol—CYP2D6—brain—epilepsy syndrome	0.000103	0.002	CbGeAlD
Zuclopenthixol—Propericiazine—ADRA2A—epilepsy syndrome	9.93e-05	0.0243	CrCbGaD
Zuclopenthixol—Clozapine—HRH3—epilepsy syndrome	9.08e-05	0.0223	CrCbGaD
Zuclopenthixol—Amoxapine—GABRA1—epilepsy syndrome	8.3e-05	0.0203	CrCbGaD
Zuclopenthixol—Amoxapine—CHRM1—epilepsy syndrome	7.74e-05	0.019	CrCbGaD
Zuclopenthixol—Chlorprothixene—CHRM3—epilepsy syndrome	7.43e-05	0.0182	CrCbGaD
Zuclopenthixol—Flupentixol—HTR2A—epilepsy syndrome	7.42e-05	0.0182	CrCbGaD
Zuclopenthixol—Hydroxyzine—CYP2D6—epilepsy syndrome	7.09e-05	0.0174	CrCbGaD
Zuclopenthixol—Nefazodone—ADRA2A—epilepsy syndrome	7.08e-05	0.0173	CrCbGaD
Zuclopenthixol—Chlorprothixene—CHRM1—epilepsy syndrome	6.93e-05	0.017	CrCbGaD
Zuclopenthixol—Prochlorperazine—CHRM2—epilepsy syndrome	6.87e-05	0.0168	CrCbGaD
Zuclopenthixol—Trazodone—ADRA2A—epilepsy syndrome	6.55e-05	0.016	CrCbGaD
Zuclopenthixol—Loxapine—CHRM3—epilepsy syndrome	6.48e-05	0.0159	CrCbGaD
Zuclopenthixol—Quetiapine—CHRM3—epilepsy syndrome	6.33e-05	0.0155	CrCbGaD
Zuclopenthixol—Amoxapine—HTR7—epilepsy syndrome	6.29e-05	0.0154	CrCbGaD
Zuclopenthixol—Thiothixene—ADRA2A—epilepsy syndrome	6.13e-05	0.015	CrCbGaD
Zuclopenthixol—Loxapine—CHRM1—epilepsy syndrome	6.04e-05	0.0148	CrCbGaD
Zuclopenthixol—Quetiapine—CHRM1—epilepsy syndrome	5.9e-05	0.0145	CrCbGaD
Zuclopenthixol—Chlorprothixene—CHRM2—epilepsy syndrome	5.66e-05	0.0139	CrCbGaD
Zuclopenthixol—Clozapine—CHRM3—epilepsy syndrome	5.44e-05	0.0133	CrCbGaD
Zuclopenthixol—Nefazodone—SLC6A4—epilepsy syndrome	5.4e-05	0.0132	CrCbGaD
Zuclopenthixol—Amoxapine—ADRA2A—epilepsy syndrome	5.39e-05	0.0132	CrCbGaD
Zuclopenthixol—Thioridazine—CHRM2—epilepsy syndrome	5.35e-05	0.0131	CrCbGaD
Zuclopenthixol—Thioridazine—HTR7—epilepsy syndrome	5.33e-05	0.0131	CrCbGaD
Zuclopenthixol—Fluphenazine—ADRA2A—epilepsy syndrome	5.3e-05	0.013	CrCbGaD
Zuclopenthixol—Chlorpromazine—CHRM3—epilepsy syndrome	5.12e-05	0.0125	CrCbGaD
Zuclopenthixol—Clozapine—CHRM1—epilepsy syndrome	5.07e-05	0.0124	CrCbGaD
Zuclopenthixol—Trazodone—SLC6A4—epilepsy syndrome	4.99e-05	0.0122	CrCbGaD
Zuclopenthixol—Trifluoperazine—CHRM2—epilepsy syndrome	4.97e-05	0.0122	CrCbGaD
Zuclopenthixol—Loxapine—CHRM2—epilepsy syndrome	4.94e-05	0.0121	CrCbGaD
Zuclopenthixol—Loxapine—HTR7—epilepsy syndrome	4.91e-05	0.012	CrCbGaD
Zuclopenthixol—Perphenazine—HTR7—epilepsy syndrome	4.89e-05	0.012	CrCbGaD
Zuclopenthixol—Flupentixol—ABCB1—epilepsy syndrome	4.85e-05	0.0119	CrCbGaD
Zuclopenthixol—Quetiapine—CHRM2—epilepsy syndrome	4.82e-05	0.0118	CrCbGaD
Zuclopenthixol—Quetiapine—HTR7—epilepsy syndrome	4.79e-05	0.0118	CrCbGaD
Zuclopenthixol—Chlorpromazine—CHRM1—epilepsy syndrome	4.77e-05	0.0117	CrCbGaD
Zuclopenthixol—Thioridazine—ADRA2A—epilepsy syndrome	4.57e-05	0.0112	CrCbGaD
Zuclopenthixol—Domperidone—CYP2D6—epilepsy syndrome	4.57e-05	0.0112	CrCbGaD
Zuclopenthixol—Pipotiazine—CYP2C19—epilepsy syndrome	4.44e-05	0.0109	CrCbGaD
Zuclopenthixol—Loxapine—ADRA2A—epilepsy syndrome	4.21e-05	0.0103	CrCbGaD
Zuclopenthixol—Perphenazine—ADRA2A—epilepsy syndrome	4.19e-05	0.0103	CrCbGaD
Zuclopenthixol—Nefazodone—HTR2A—epilepsy syndrome	4.15e-05	0.0102	CrCbGaD
Zuclopenthixol—Clozapine—CHRM2—epilepsy syndrome	4.14e-05	0.0102	CrCbGaD
Zuclopenthixol—Clozapine—HTR7—epilepsy syndrome	4.12e-05	0.0101	CrCbGaD
Zuclopenthixol—Amoxapine—SLC6A4—epilepsy syndrome	4.11e-05	0.0101	CrCbGaD
Zuclopenthixol—Quetiapine—ADRA2A—epilepsy syndrome	4.11e-05	0.0101	CrCbGaD
Zuclopenthixol—Oedema peripheral—Topiramate—epilepsy syndrome	3.93e-05	0.000217	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Valproic Acid—epilepsy syndrome	3.93e-05	0.000216	CcSEcCtD
Zuclopenthixol—Pruritus—Phenytoin—epilepsy syndrome	3.92e-05	0.000216	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Topiramate—epilepsy syndrome	3.92e-05	0.000216	CcSEcCtD
Zuclopenthixol—Nausea—Levetiracetam—epilepsy syndrome	3.92e-05	0.000216	CcSEcCtD
Zuclopenthixol—Rash—Vigabatrin—epilepsy syndrome	3.91e-05	0.000216	CcSEcCtD
Zuclopenthixol—Dizziness—Felbamate—epilepsy syndrome	3.91e-05	0.000216	CcSEcCtD
Zuclopenthixol—Dermatitis—Vigabatrin—epilepsy syndrome	3.91e-05	0.000215	CcSEcCtD
Zuclopenthixol—Urethral disorder—Topiramate—epilepsy syndrome	3.91e-05	0.000215	CcSEcCtD
Zuclopenthixol—Pruritus—Oxcarbazepine—epilepsy syndrome	3.9e-05	0.000215	CcSEcCtD
Zuclopenthixol—Convulsion—Pregabalin—epilepsy syndrome	3.9e-05	0.000215	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Carbamazepine—epilepsy syndrome	3.9e-05	0.000215	CcSEcCtD
Zuclopenthixol—Chlorpromazine—CHRM2—epilepsy syndrome	3.9e-05	0.00955	CrCbGaD
Zuclopenthixol—Vision blurred—Gabapentin—epilepsy syndrome	3.89e-05	0.000214	CcSEcCtD
Zuclopenthixol—Headache—Vigabatrin—epilepsy syndrome	3.89e-05	0.000214	CcSEcCtD
Zuclopenthixol—Hypertension—Pregabalin—epilepsy syndrome	3.89e-05	0.000214	CcSEcCtD
Zuclopenthixol—Vomiting—Diazepam—epilepsy syndrome	3.89e-05	0.000214	CcSEcCtD
Zuclopenthixol—Chlorpromazine—HTR7—epilepsy syndrome	3.88e-05	0.00951	CrCbGaD
Zuclopenthixol—Anorexia—Valproic Acid—epilepsy syndrome	3.87e-05	0.000213	CcSEcCtD
Zuclopenthixol—Tremor—Gabapentin—epilepsy syndrome	3.87e-05	0.000213	CcSEcCtD
Zuclopenthixol—Rash—Diazepam—epilepsy syndrome	3.85e-05	0.000212	CcSEcCtD
Zuclopenthixol—Dermatitis—Diazepam—epilepsy syndrome	3.85e-05	0.000212	CcSEcCtD
Zuclopenthixol—Visual impairment—Topiramate—epilepsy syndrome	3.84e-05	0.000212	CcSEcCtD
Zuclopenthixol—Trazodone—HTR2A—epilepsy syndrome	3.84e-05	0.00941	CrCbGaD
Zuclopenthixol—Myalgia—Pregabalin—epilepsy syndrome	3.83e-05	0.000211	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Gabapentin—epilepsy syndrome	3.83e-05	0.000211	CcSEcCtD
Zuclopenthixol—Dizziness—Zonisamide—epilepsy syndrome	3.83e-05	0.000211	CcSEcCtD
Zuclopenthixol—Headache—Diazepam—epilepsy syndrome	3.83e-05	0.000211	CcSEcCtD
Zuclopenthixol—Anxiety—Pregabalin—epilepsy syndrome	3.82e-05	0.00021	CcSEcCtD
Zuclopenthixol—Diarrhoea—Clonazepam—epilepsy syndrome	3.82e-05	0.00021	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	3.81e-05	0.00021	CcSEcCtD
Zuclopenthixol—Hypotension—Valproic Acid—epilepsy syndrome	3.8e-05	0.000209	CcSEcCtD
Zuclopenthixol—Asthenia—Carbamazepine—epilepsy syndrome	3.8e-05	0.000209	CcSEcCtD
Zuclopenthixol—Nefazodone—CYP2D6—epilepsy syndrome	3.79e-05	0.0093	CrCbGaD
Zuclopenthixol—Agitation—Gabapentin—epilepsy syndrome	3.79e-05	0.000209	CcSEcCtD
Zuclopenthixol—Diarrhoea—Phenytoin—epilepsy syndrome	3.79e-05	0.000209	CcSEcCtD
Zuclopenthixol—Discomfort—Pregabalin—epilepsy syndrome	3.79e-05	0.000209	CcSEcCtD
Zuclopenthixol—Nausea—Fosphenytoin—epilepsy syndrome	3.78e-05	0.000208	CcSEcCtD
Zuclopenthixol—Diarrhoea—Oxcarbazepine—epilepsy syndrome	3.77e-05	0.000208	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Lamotrigine—epilepsy syndrome	3.77e-05	0.000208	CcSEcCtD
Zuclopenthixol—Vomiting—Felbamate—epilepsy syndrome	3.76e-05	0.000207	CcSEcCtD
Zuclopenthixol—Dry mouth—Pregabalin—epilepsy syndrome	3.75e-05	0.000207	CcSEcCtD
Zuclopenthixol—Pruritus—Carbamazepine—epilepsy syndrome	3.74e-05	0.000206	CcSEcCtD
Zuclopenthixol—Rash—Felbamate—epilepsy syndrome	3.73e-05	0.000206	CcSEcCtD
Zuclopenthixol—Eye disorder—Topiramate—epilepsy syndrome	3.73e-05	0.000205	CcSEcCtD
Zuclopenthixol—Dermatitis—Felbamate—epilepsy syndrome	3.73e-05	0.000205	CcSEcCtD
Zuclopenthixol—Malaise—Gabapentin—epilepsy syndrome	3.72e-05	0.000205	CcSEcCtD
Zuclopenthixol—Tinnitus—Topiramate—epilepsy syndrome	3.72e-05	0.000205	CcSEcCtD
Zuclopenthixol—Vertigo—Gabapentin—epilepsy syndrome	3.71e-05	0.000204	CcSEcCtD
Zuclopenthixol—Headache—Felbamate—epilepsy syndrome	3.71e-05	0.000204	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	3.7e-05	0.000204	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Topiramate—epilepsy syndrome	3.7e-05	0.000204	CcSEcCtD
Zuclopenthixol—Syncope—Gabapentin—epilepsy syndrome	3.7e-05	0.000204	CcSEcCtD
Zuclopenthixol—Leukopenia—Gabapentin—epilepsy syndrome	3.69e-05	0.000204	CcSEcCtD
Zuclopenthixol—Dizziness—Clonazepam—epilepsy syndrome	3.69e-05	0.000203	CcSEcCtD
Zuclopenthixol—Nausea—Vigabatrin—epilepsy syndrome	3.69e-05	0.000203	CcSEcCtD
Zuclopenthixol—Vomiting—Zonisamide—epilepsy syndrome	3.68e-05	0.000203	CcSEcCtD
Zuclopenthixol—Insomnia—Valproic Acid—epilepsy syndrome	3.68e-05	0.000203	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Pregabalin—epilepsy syndrome	3.67e-05	0.000202	CcSEcCtD
Zuclopenthixol—Asthenia—Lamotrigine—epilepsy syndrome	3.67e-05	0.000202	CcSEcCtD
Zuclopenthixol—Dizziness—Phenytoin—epilepsy syndrome	3.67e-05	0.000202	CcSEcCtD
Zuclopenthixol—Thioproperazine—HTR2A—epilepsy syndrome	3.66e-05	0.00896	CrCbGaD
Zuclopenthixol—Rash—Zonisamide—epilepsy syndrome	3.65e-05	0.000201	CcSEcCtD
Zuclopenthixol—Paraesthesia—Valproic Acid—epilepsy syndrome	3.65e-05	0.000201	CcSEcCtD
Zuclopenthixol—Palpitations—Gabapentin—epilepsy syndrome	3.65e-05	0.000201	CcSEcCtD
Zuclopenthixol—Dermatitis—Zonisamide—epilepsy syndrome	3.65e-05	0.000201	CcSEcCtD
Zuclopenthixol—Dizziness—Oxcarbazepine—epilepsy syndrome	3.65e-05	0.000201	CcSEcCtD
Zuclopenthixol—Nausea—Diazepam—epilepsy syndrome	3.63e-05	0.0002	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Gabapentin—epilepsy syndrome	3.63e-05	0.0002	CcSEcCtD
Zuclopenthixol—Headache—Zonisamide—epilepsy syndrome	3.63e-05	0.0002	CcSEcCtD
Zuclopenthixol—Dyspnoea—Valproic Acid—epilepsy syndrome	3.62e-05	0.0002	CcSEcCtD
Zuclopenthixol—Diarrhoea—Carbamazepine—epilepsy syndrome	3.62e-05	0.000199	CcSEcCtD
Zuclopenthixol—Angiopathy—Topiramate—epilepsy syndrome	3.62e-05	0.000199	CcSEcCtD
Zuclopenthixol—Pruritus—Lamotrigine—epilepsy syndrome	3.62e-05	0.000199	CcSEcCtD
Zuclopenthixol—Shock—Pregabalin—epilepsy syndrome	3.61e-05	0.000199	CcSEcCtD
Zuclopenthixol—Somnolence—Valproic Acid—epilepsy syndrome	3.61e-05	0.000199	CcSEcCtD
Zuclopenthixol—Immune system disorder—Topiramate—epilepsy syndrome	3.6e-05	0.000199	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Pregabalin—epilepsy syndrome	3.6e-05	0.000199	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Pregabalin—epilepsy syndrome	3.6e-05	0.000198	CcSEcCtD
Zuclopenthixol—Thiothixene—HTR2A—epilepsy syndrome	3.6e-05	0.00882	CrCbGaD
Zuclopenthixol—Pipotiazine—HTR2A—epilepsy syndrome	3.6e-05	0.00882	CrCbGaD
Zuclopenthixol—Tachycardia—Pregabalin—epilepsy syndrome	3.59e-05	0.000198	CcSEcCtD
Zuclopenthixol—Dyspepsia—Valproic Acid—epilepsy syndrome	3.58e-05	0.000197	CcSEcCtD
Zuclopenthixol—Convulsion—Gabapentin—epilepsy syndrome	3.58e-05	0.000197	CcSEcCtD
Zuclopenthixol—Skin disorder—Pregabalin—epilepsy syndrome	3.57e-05	0.000197	CcSEcCtD
Zuclopenthixol—Hypertension—Gabapentin—epilepsy syndrome	3.56e-05	0.000196	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Pregabalin—epilepsy syndrome	3.55e-05	0.000196	CcSEcCtD
Zuclopenthixol—Vomiting—Clonazepam—epilepsy syndrome	3.55e-05	0.000196	CcSEcCtD
Zuclopenthixol—Clozapine—ADRA2A—epilepsy syndrome	3.54e-05	0.00867	CrCbGaD
Zuclopenthixol—Decreased appetite—Valproic Acid—epilepsy syndrome	3.53e-05	0.000195	CcSEcCtD
Zuclopenthixol—Vomiting—Phenytoin—epilepsy syndrome	3.52e-05	0.000194	CcSEcCtD
Zuclopenthixol—Rash—Clonazepam—epilepsy syndrome	3.52e-05	0.000194	CcSEcCtD
Zuclopenthixol—Dermatitis—Clonazepam—epilepsy syndrome	3.52e-05	0.000194	CcSEcCtD
Zuclopenthixol—Myalgia—Gabapentin—epilepsy syndrome	3.51e-05	0.000194	CcSEcCtD
Zuclopenthixol—Nausea—Felbamate—epilepsy syndrome	3.51e-05	0.000194	CcSEcCtD
Zuclopenthixol—Trazodone—CYP2D6—epilepsy syndrome	3.51e-05	0.0086	CrCbGaD
Zuclopenthixol—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.51e-05	0.000193	CcSEcCtD
Zuclopenthixol—Vomiting—Oxcarbazepine—epilepsy syndrome	3.51e-05	0.000193	CcSEcCtD
Zuclopenthixol—Fatigue—Valproic Acid—epilepsy syndrome	3.5e-05	0.000193	CcSEcCtD
Zuclopenthixol—Anxiety—Gabapentin—epilepsy syndrome	3.5e-05	0.000193	CcSEcCtD
Zuclopenthixol—Anorexia—Pregabalin—epilepsy syndrome	3.5e-05	0.000193	CcSEcCtD
Zuclopenthixol—Dizziness—Carbamazepine—epilepsy syndrome	3.5e-05	0.000193	CcSEcCtD
Zuclopenthixol—Diarrhoea—Lamotrigine—epilepsy syndrome	3.5e-05	0.000193	CcSEcCtD
Zuclopenthixol—Headache—Clonazepam—epilepsy syndrome	3.5e-05	0.000193	CcSEcCtD
Zuclopenthixol—Rash—Phenytoin—epilepsy syndrome	3.5e-05	0.000193	CcSEcCtD
Zuclopenthixol—Mental disorder—Topiramate—epilepsy syndrome	3.49e-05	0.000193	CcSEcCtD
Zuclopenthixol—Dermatitis—Phenytoin—epilepsy syndrome	3.49e-05	0.000192	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	3.49e-05	0.000192	CcSEcCtD
Zuclopenthixol—Rash—Oxcarbazepine—epilepsy syndrome	3.48e-05	0.000192	CcSEcCtD
Zuclopenthixol—Constipation—Valproic Acid—epilepsy syndrome	3.48e-05	0.000191	CcSEcCtD
Zuclopenthixol—Pain—Valproic Acid—epilepsy syndrome	3.48e-05	0.000191	CcSEcCtD
Zuclopenthixol—Dermatitis—Oxcarbazepine—epilepsy syndrome	3.47e-05	0.000191	CcSEcCtD
Zuclopenthixol—Headache—Phenytoin—epilepsy syndrome	3.47e-05	0.000191	CcSEcCtD
Zuclopenthixol—Erythema—Topiramate—epilepsy syndrome	3.47e-05	0.000191	CcSEcCtD
Zuclopenthixol—Malnutrition—Topiramate—epilepsy syndrome	3.47e-05	0.000191	CcSEcCtD
Zuclopenthixol—Discomfort—Gabapentin—epilepsy syndrome	3.47e-05	0.000191	CcSEcCtD
Zuclopenthixol—Headache—Oxcarbazepine—epilepsy syndrome	3.45e-05	0.00019	CcSEcCtD
Zuclopenthixol—Nausea—Zonisamide—epilepsy syndrome	3.44e-05	0.00019	CcSEcCtD
Zuclopenthixol—Dry mouth—Gabapentin—epilepsy syndrome	3.44e-05	0.000189	CcSEcCtD
Zuclopenthixol—Hypotension—Pregabalin—epilepsy syndrome	3.43e-05	0.000189	CcSEcCtD
Zuclopenthixol—Flatulence—Topiramate—epilepsy syndrome	3.42e-05	0.000189	CcSEcCtD
Zuclopenthixol—Tension—Topiramate—epilepsy syndrome	3.41e-05	0.000188	CcSEcCtD
Zuclopenthixol—Dizziness—Lamotrigine—epilepsy syndrome	3.38e-05	0.000186	CcSEcCtD
Zuclopenthixol—Nervousness—Topiramate—epilepsy syndrome	3.37e-05	0.000186	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Gabapentin—epilepsy syndrome	3.37e-05	0.000186	CcSEcCtD
Zuclopenthixol—Vomiting—Carbamazepine—epilepsy syndrome	3.36e-05	0.000185	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Valproic Acid—epilepsy syndrome	3.35e-05	0.000185	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	3.35e-05	0.000184	CcSEcCtD
Zuclopenthixol—Rash—Carbamazepine—epilepsy syndrome	3.34e-05	0.000184	CcSEcCtD
Zuclopenthixol—Dermatitis—Carbamazepine—epilepsy syndrome	3.33e-05	0.000184	CcSEcCtD
Zuclopenthixol—Chlorpromazine—ADRA2A—epilepsy syndrome	3.33e-05	0.00815	CrCbGaD
Zuclopenthixol—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	3.32e-05	0.000183	CcSEcCtD
Zuclopenthixol—Insomnia—Pregabalin—epilepsy syndrome	3.32e-05	0.000183	CcSEcCtD
Zuclopenthixol—Nausea—Clonazepam—epilepsy syndrome	3.31e-05	0.000183	CcSEcCtD
Zuclopenthixol—Headache—Carbamazepine—epilepsy syndrome	3.31e-05	0.000183	CcSEcCtD
Zuclopenthixol—Shock—Gabapentin—epilepsy syndrome	3.31e-05	0.000183	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Gabapentin—epilepsy syndrome	3.3e-05	0.000182	CcSEcCtD
Zuclopenthixol—Thioridazine—CYP2C19—epilepsy syndrome	3.3e-05	0.0081	CrCbGaD
Zuclopenthixol—Paraesthesia—Pregabalin—epilepsy syndrome	3.3e-05	0.000182	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Gabapentin—epilepsy syndrome	3.3e-05	0.000182	CcSEcCtD
Zuclopenthixol—Nausea—Phenytoin—epilepsy syndrome	3.29e-05	0.000181	CcSEcCtD
Zuclopenthixol—Thiothixene—CYP2D6—epilepsy syndrome	3.29e-05	0.00806	CrCbGaD
Zuclopenthixol—Pipotiazine—CYP2D6—epilepsy syndrome	3.29e-05	0.00806	CrCbGaD
Zuclopenthixol—Tachycardia—Gabapentin—epilepsy syndrome	3.29e-05	0.000181	CcSEcCtD
Zuclopenthixol—Dyspnoea—Pregabalin—epilepsy syndrome	3.28e-05	0.00018	CcSEcCtD
Zuclopenthixol—Nausea—Oxcarbazepine—epilepsy syndrome	3.28e-05	0.00018	CcSEcCtD
Zuclopenthixol—Vision blurred—Topiramate—epilepsy syndrome	3.27e-05	0.00018	CcSEcCtD
Zuclopenthixol—Skin disorder—Gabapentin—epilepsy syndrome	3.27e-05	0.00018	CcSEcCtD
Zuclopenthixol—Somnolence—Pregabalin—epilepsy syndrome	3.27e-05	0.00018	CcSEcCtD
Zuclopenthixol—Domperidone—ABCB1—epilepsy syndrome	3.26e-05	0.008	CrCbGaD
Zuclopenthixol—Hyperhidrosis—Gabapentin—epilepsy syndrome	3.26e-05	0.000179	CcSEcCtD
Zuclopenthixol—Tremor—Topiramate—epilepsy syndrome	3.25e-05	0.000179	CcSEcCtD
Zuclopenthixol—Vomiting—Lamotrigine—epilepsy syndrome	3.25e-05	0.000179	CcSEcCtD
Zuclopenthixol—Chlorpromazine—BCHE—epilepsy syndrome	3.25e-05	0.00797	CrCbGaD
Zuclopenthixol—Rash—Lamotrigine—epilepsy syndrome	3.22e-05	0.000178	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Topiramate—epilepsy syndrome	3.22e-05	0.000178	CcSEcCtD
Zuclopenthixol—Dermatitis—Lamotrigine—epilepsy syndrome	3.22e-05	0.000178	CcSEcCtD
Zuclopenthixol—Loxapine—SLC6A4—epilepsy syndrome	3.21e-05	0.00788	CrCbGaD
Zuclopenthixol—Abdominal pain—Valproic Acid—epilepsy syndrome	3.21e-05	0.000177	CcSEcCtD
Zuclopenthixol—Body temperature increased—Valproic Acid—epilepsy syndrome	3.21e-05	0.000177	CcSEcCtD
Zuclopenthixol—Anorexia—Gabapentin—epilepsy syndrome	3.21e-05	0.000177	CcSEcCtD
Zuclopenthixol—Headache—Lamotrigine—epilepsy syndrome	3.2e-05	0.000177	CcSEcCtD
Zuclopenthixol—Decreased appetite—Pregabalin—epilepsy syndrome	3.19e-05	0.000176	CcSEcCtD
Zuclopenthixol—Agitation—Topiramate—epilepsy syndrome	3.19e-05	0.000176	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.17e-05	0.000175	CcSEcCtD
Zuclopenthixol—Fatigue—Pregabalin—epilepsy syndrome	3.17e-05	0.000175	CcSEcCtD
Zuclopenthixol—Amoxapine—HTR2A—epilepsy syndrome	3.16e-05	0.00775	CrCbGaD
Zuclopenthixol—Hypotension—Gabapentin—epilepsy syndrome	3.15e-05	0.000173	CcSEcCtD
Zuclopenthixol—Prochlorperazine—CYP2D6—epilepsy syndrome	3.14e-05	0.00771	CrCbGaD
Zuclopenthixol—Nausea—Carbamazepine—epilepsy syndrome	3.14e-05	0.000173	CcSEcCtD
Zuclopenthixol—Pain—Pregabalin—epilepsy syndrome	3.14e-05	0.000173	CcSEcCtD
Zuclopenthixol—Constipation—Pregabalin—epilepsy syndrome	3.14e-05	0.000173	CcSEcCtD
Zuclopenthixol—Malaise—Topiramate—epilepsy syndrome	3.13e-05	0.000173	CcSEcCtD
Zuclopenthixol—Vertigo—Topiramate—epilepsy syndrome	3.12e-05	0.000172	CcSEcCtD
Zuclopenthixol—Syncope—Topiramate—epilepsy syndrome	3.11e-05	0.000172	CcSEcCtD
Zuclopenthixol—Leukopenia—Topiramate—epilepsy syndrome	3.11e-05	0.000171	CcSEcCtD
Zuclopenthixol—Fluphenazine—HTR2A—epilepsy syndrome	3.11e-05	0.00762	CrCbGaD
Zuclopenthixol—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	3.07e-05	0.000169	CcSEcCtD
Zuclopenthixol—Palpitations—Topiramate—epilepsy syndrome	3.07e-05	0.000169	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Topiramate—epilepsy syndrome	3.05e-05	0.000168	CcSEcCtD
Zuclopenthixol—Insomnia—Gabapentin—epilepsy syndrome	3.05e-05	0.000168	CcSEcCtD
Zuclopenthixol—Nausea—Lamotrigine—epilepsy syndrome	3.04e-05	0.000167	CcSEcCtD
Zuclopenthixol—Perphenazine—CYP2C19—epilepsy syndrome	3.03e-05	0.00743	CrCbGaD
Zuclopenthixol—Feeling abnormal—Pregabalin—epilepsy syndrome	3.03e-05	0.000167	CcSEcCtD
Zuclopenthixol—Paraesthesia—Gabapentin—epilepsy syndrome	3.02e-05	0.000167	CcSEcCtD
Zuclopenthixol—Convulsion—Topiramate—epilepsy syndrome	3.01e-05	0.000166	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Pregabalin—epilepsy syndrome	3e-05	0.000166	CcSEcCtD
Zuclopenthixol—Dyspnoea—Gabapentin—epilepsy syndrome	3e-05	0.000165	CcSEcCtD
Zuclopenthixol—Hypertension—Topiramate—epilepsy syndrome	3e-05	0.000165	CcSEcCtD
Zuclopenthixol—Somnolence—Gabapentin—epilepsy syndrome	2.99e-05	0.000165	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Valproic Acid—epilepsy syndrome	2.99e-05	0.000165	CcSEcCtD
Zuclopenthixol—Quetiapine—CYP2C19—epilepsy syndrome	2.97e-05	0.00729	CrCbGaD
Zuclopenthixol—Dyspepsia—Gabapentin—epilepsy syndrome	2.97e-05	0.000163	CcSEcCtD
Zuclopenthixol—Myalgia—Topiramate—epilepsy syndrome	2.96e-05	0.000163	CcSEcCtD
Zuclopenthixol—Anxiety—Topiramate—epilepsy syndrome	2.95e-05	0.000162	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	2.94e-05	0.000162	CcSEcCtD
Zuclopenthixol—Decreased appetite—Gabapentin—epilepsy syndrome	2.93e-05	0.000161	CcSEcCtD
Zuclopenthixol—Discomfort—Topiramate—epilepsy syndrome	2.92e-05	0.000161	CcSEcCtD
Zuclopenthixol—Asthenia—Valproic Acid—epilepsy syndrome	2.92e-05	0.000161	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.91e-05	0.00016	CcSEcCtD
Zuclopenthixol—Fatigue—Gabapentin—epilepsy syndrome	2.9e-05	0.00016	CcSEcCtD
Zuclopenthixol—Abdominal pain—Pregabalin—epilepsy syndrome	2.9e-05	0.00016	CcSEcCtD
Zuclopenthixol—Body temperature increased—Pregabalin—epilepsy syndrome	2.9e-05	0.00016	CcSEcCtD
Zuclopenthixol—Dry mouth—Topiramate—epilepsy syndrome	2.89e-05	0.000159	CcSEcCtD
Zuclopenthixol—Amoxapine—CYP2D6—epilepsy syndrome	2.89e-05	0.00709	CrCbGaD
Zuclopenthixol—Pain—Gabapentin—epilepsy syndrome	2.88e-05	0.000159	CcSEcCtD
Zuclopenthixol—Constipation—Gabapentin—epilepsy syndrome	2.88e-05	0.000159	CcSEcCtD
Zuclopenthixol—Pruritus—Valproic Acid—epilepsy syndrome	2.88e-05	0.000158	CcSEcCtD
Zuclopenthixol—Fluphenazine—CYP2D6—epilepsy syndrome	2.84e-05	0.00697	CrCbGaD
Zuclopenthixol—Chlorprothixene—HTR2A—epilepsy syndrome	2.83e-05	0.00694	CrCbGaD
Zuclopenthixol—Shock—Topiramate—epilepsy syndrome	2.79e-05	0.000154	CcSEcCtD
Zuclopenthixol—Diarrhoea—Valproic Acid—epilepsy syndrome	2.78e-05	0.000153	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Topiramate—epilepsy syndrome	2.78e-05	0.000153	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Gabapentin—epilepsy syndrome	2.78e-05	0.000153	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Topiramate—epilepsy syndrome	2.77e-05	0.000153	CcSEcCtD
Zuclopenthixol—Tachycardia—Topiramate—epilepsy syndrome	2.77e-05	0.000152	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Gabapentin—epilepsy syndrome	2.75e-05	0.000152	CcSEcCtD
Zuclopenthixol—Skin disorder—Topiramate—epilepsy syndrome	2.75e-05	0.000152	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Topiramate—epilepsy syndrome	2.74e-05	0.000151	CcSEcCtD
Zuclopenthixol—Nefazodone—ABCB1—epilepsy syndrome	2.71e-05	0.00664	CrCbGaD
Zuclopenthixol—Hypersensitivity—Pregabalin—epilepsy syndrome	2.71e-05	0.000149	CcSEcCtD
Zuclopenthixol—Anorexia—Topiramate—epilepsy syndrome	2.7e-05	0.000149	CcSEcCtD
Zuclopenthixol—Dizziness—Valproic Acid—epilepsy syndrome	2.69e-05	0.000148	CcSEcCtD
Zuclopenthixol—Thioridazine—HTR2A—epilepsy syndrome	2.68e-05	0.00656	CrCbGaD
Zuclopenthixol—Abdominal pain—Gabapentin—epilepsy syndrome	2.66e-05	0.000147	CcSEcCtD
Zuclopenthixol—Body temperature increased—Gabapentin—epilepsy syndrome	2.66e-05	0.000147	CcSEcCtD
Zuclopenthixol—Hypotension—Topiramate—epilepsy syndrome	2.65e-05	0.000146	CcSEcCtD
Zuclopenthixol—Asthenia—Pregabalin—epilepsy syndrome	2.64e-05	0.000145	CcSEcCtD
Zuclopenthixol—Pruritus—Pregabalin—epilepsy syndrome	2.6e-05	0.000143	CcSEcCtD
Zuclopenthixol—Vomiting—Valproic Acid—epilepsy syndrome	2.58e-05	0.000142	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	2.58e-05	0.000142	CcSEcCtD
Zuclopenthixol—Insomnia—Topiramate—epilepsy syndrome	2.56e-05	0.000141	CcSEcCtD
Zuclopenthixol—Rash—Valproic Acid—epilepsy syndrome	2.56e-05	0.000141	CcSEcCtD
Zuclopenthixol—Dermatitis—Valproic Acid—epilepsy syndrome	2.56e-05	0.000141	CcSEcCtD
Zuclopenthixol—Clozapine—CYP2C19—epilepsy syndrome	2.56e-05	0.00627	CrCbGaD
Zuclopenthixol—Headache—Valproic Acid—epilepsy syndrome	2.55e-05	0.00014	CcSEcCtD
Zuclopenthixol—Paraesthesia—Topiramate—epilepsy syndrome	2.54e-05	0.00014	CcSEcCtD
Zuclopenthixol—Dyspnoea—Topiramate—epilepsy syndrome	2.53e-05	0.000139	CcSEcCtD
Zuclopenthixol—Somnolence—Topiramate—epilepsy syndrome	2.52e-05	0.000139	CcSEcCtD
Zuclopenthixol—Diarrhoea—Pregabalin—epilepsy syndrome	2.51e-05	0.000139	CcSEcCtD
Zuclopenthixol—Trazodone—ABCB1—epilepsy syndrome	2.51e-05	0.00614	CrCbGaD
Zuclopenthixol—Thioproperazine—ALB—epilepsy syndrome	2.5e-05	0.00613	CrCbGaD
Zuclopenthixol—Dyspepsia—Topiramate—epilepsy syndrome	2.49e-05	0.000137	CcSEcCtD
Zuclopenthixol—Trifluoperazine—HTR2A—epilepsy syndrome	2.48e-05	0.00609	CrCbGaD
Zuclopenthixol—Hypersensitivity—Gabapentin—epilepsy syndrome	2.48e-05	0.000137	CcSEcCtD
Zuclopenthixol—Loxapine—HTR2A—epilepsy syndrome	2.47e-05	0.00605	CrCbGaD
Zuclopenthixol—Decreased appetite—Topiramate—epilepsy syndrome	2.46e-05	0.000136	CcSEcCtD
Zuclopenthixol—Thiothixene—ALB—epilepsy syndrome	2.46e-05	0.00603	CrCbGaD
Zuclopenthixol—Pipotiazine—ALB—epilepsy syndrome	2.46e-05	0.00603	CrCbGaD
Zuclopenthixol—Perphenazine—HTR2A—epilepsy syndrome	2.46e-05	0.00603	CrCbGaD
Zuclopenthixol—Thioridazine—CYP2D6—epilepsy syndrome	2.45e-05	0.006	CrCbGaD
Zuclopenthixol—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.45e-05	0.000135	CcSEcCtD
Zuclopenthixol—Fatigue—Topiramate—epilepsy syndrome	2.44e-05	0.000135	CcSEcCtD
Zuclopenthixol—Dizziness—Pregabalin—epilepsy syndrome	2.43e-05	0.000134	CcSEcCtD
Zuclopenthixol—Constipation—Topiramate—epilepsy syndrome	2.42e-05	0.000134	CcSEcCtD
Zuclopenthixol—Pain—Topiramate—epilepsy syndrome	2.42e-05	0.000134	CcSEcCtD
Zuclopenthixol—Asthenia—Gabapentin—epilepsy syndrome	2.42e-05	0.000133	CcSEcCtD
Zuclopenthixol—Nausea—Valproic Acid—epilepsy syndrome	2.41e-05	0.000133	CcSEcCtD
Zuclopenthixol—Quetiapine—HTR2A—epilepsy syndrome	2.41e-05	0.00591	CrCbGaD
Zuclopenthixol—Pruritus—Gabapentin—epilepsy syndrome	2.38e-05	0.000131	CcSEcCtD
Zuclopenthixol—Vomiting—Pregabalin—epilepsy syndrome	2.34e-05	0.000129	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Topiramate—epilepsy syndrome	2.34e-05	0.000129	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.32e-05	0.000128	CcSEcCtD
Zuclopenthixol—Rash—Pregabalin—epilepsy syndrome	2.32e-05	0.000128	CcSEcCtD
Zuclopenthixol—Dermatitis—Pregabalin—epilepsy syndrome	2.31e-05	0.000128	CcSEcCtD
Zuclopenthixol—Diarrhoea—Gabapentin—epilepsy syndrome	2.3e-05	0.000127	CcSEcCtD
Zuclopenthixol—Headache—Pregabalin—epilepsy syndrome	2.3e-05	0.000127	CcSEcCtD
Zuclopenthixol—Perphenazine—CYP2D6—epilepsy syndrome	2.25e-05	0.00551	CrCbGaD
Zuclopenthixol—Abdominal pain—Topiramate—epilepsy syndrome	2.24e-05	0.000123	CcSEcCtD
Zuclopenthixol—Body temperature increased—Topiramate—epilepsy syndrome	2.24e-05	0.000123	CcSEcCtD
Zuclopenthixol—Dizziness—Gabapentin—epilepsy syndrome	2.23e-05	0.000123	CcSEcCtD
Zuclopenthixol—Quetiapine—CYP2D6—epilepsy syndrome	2.2e-05	0.0054	CrCbGaD
Zuclopenthixol—Nausea—Pregabalin—epilepsy syndrome	2.18e-05	0.00012	CcSEcCtD
Zuclopenthixol—Vomiting—Gabapentin—epilepsy syndrome	2.14e-05	0.000118	CcSEcCtD
Zuclopenthixol—Rash—Gabapentin—epilepsy syndrome	2.12e-05	0.000117	CcSEcCtD
Zuclopenthixol—Dermatitis—Gabapentin—epilepsy syndrome	2.12e-05	0.000117	CcSEcCtD
Zuclopenthixol—Headache—Gabapentin—epilepsy syndrome	2.11e-05	0.000116	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Topiramate—epilepsy syndrome	2.09e-05	0.000115	CcSEcCtD
Zuclopenthixol—Clozapine—HTR2A—epilepsy syndrome	2.07e-05	0.00508	CrCbGaD
Zuclopenthixol—Asthenia—Topiramate—epilepsy syndrome	2.03e-05	0.000112	CcSEcCtD
Zuclopenthixol—Fluphenazine—ABCB1—epilepsy syndrome	2.03e-05	0.00498	CrCbGaD
Zuclopenthixol—Pruritus—Topiramate—epilepsy syndrome	2.01e-05	0.00011	CcSEcCtD
Zuclopenthixol—Nausea—Gabapentin—epilepsy syndrome	2e-05	0.00011	CcSEcCtD
Zuclopenthixol—Chlorpromazine—HTR2A—epilepsy syndrome	1.95e-05	0.00478	CrCbGaD
Zuclopenthixol—Diarrhoea—Topiramate—epilepsy syndrome	1.94e-05	0.000107	CcSEcCtD
Zuclopenthixol—Clozapine—CYP2D6—epilepsy syndrome	1.9e-05	0.00465	CrCbGaD
Zuclopenthixol—Dizziness—Topiramate—epilepsy syndrome	1.87e-05	0.000103	CcSEcCtD
Zuclopenthixol—Chlorprothixene—ABCB1—epilepsy syndrome	1.85e-05	0.00453	CrCbGaD
Zuclopenthixol—Vomiting—Topiramate—epilepsy syndrome	1.8e-05	9.93e-05	CcSEcCtD
Zuclopenthixol—Rash—Topiramate—epilepsy syndrome	1.79e-05	9.85e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Topiramate—epilepsy syndrome	1.79e-05	9.84e-05	CcSEcCtD
Zuclopenthixol—Chlorpromazine—CYP2D6—epilepsy syndrome	1.78e-05	0.00437	CrCbGaD
Zuclopenthixol—Headache—Topiramate—epilepsy syndrome	1.78e-05	9.78e-05	CcSEcCtD
Zuclopenthixol—Nausea—Topiramate—epilepsy syndrome	1.68e-05	9.28e-05	CcSEcCtD
Zuclopenthixol—Trifluoperazine—ABCB1—epilepsy syndrome	1.62e-05	0.00398	CrCbGaD
Zuclopenthixol—Quetiapine—ABCB1—epilepsy syndrome	1.57e-05	0.00386	CrCbGaD
Zuclopenthixol—Clozapine—ABCB1—epilepsy syndrome	1.35e-05	0.00332	CrCbGaD
Zuclopenthixol—Chlorpromazine—ALB—epilepsy syndrome	1.33e-05	0.00327	CrCbGaD
Zuclopenthixol—Chlorpromazine—ABCB1—epilepsy syndrome	1.27e-05	0.00312	CrCbGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—POMC—epilepsy syndrome	3.83e-06	4.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ADAM10—epilepsy syndrome	3.82e-06	4.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PRKCB—epilepsy syndrome	3.82e-06	4.58e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—POMC—epilepsy syndrome	3.82e-06	4.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—VEGFA—epilepsy syndrome	3.81e-06	4.57e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HTR2A—epilepsy syndrome	3.81e-06	4.57e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6ST—epilepsy syndrome	3.81e-06	4.56e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CCL2—epilepsy syndrome	3.81e-06	4.56e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT3—epilepsy syndrome	3.77e-06	4.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JUNB—epilepsy syndrome	3.77e-06	4.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CNR1—epilepsy syndrome	3.77e-06	4.52e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ADAM10—epilepsy syndrome	3.76e-06	4.51e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—RELA—epilepsy syndrome	3.76e-06	4.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PLCB1—epilepsy syndrome	3.76e-06	4.5e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ADAM10—epilepsy syndrome	3.75e-06	4.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—POMC—epilepsy syndrome	3.75e-06	4.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CCL2—epilepsy syndrome	3.74e-06	4.49e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	3.74e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CCL2—epilepsy syndrome	3.74e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—HMOX1—epilepsy syndrome	3.74e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MTOR—epilepsy syndrome	3.69e-06	4.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CAT—epilepsy syndrome	3.69e-06	4.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ADAM10—epilepsy syndrome	3.68e-06	4.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HTR7—epilepsy syndrome	3.68e-06	4.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CCL2—epilepsy syndrome	3.67e-06	4.39e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	3.65e-06	4.37e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	3.63e-06	4.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TSC2—epilepsy syndrome	3.62e-06	4.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AGT—epilepsy syndrome	3.62e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—S100B—epilepsy syndrome	3.62e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ABCB1—epilepsy syndrome	3.59e-06	4.3e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SOCS3—epilepsy syndrome	3.58e-06	4.29e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDC42—epilepsy syndrome	3.57e-06	4.28e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HBEGF—epilepsy syndrome	3.57e-06	4.28e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—S100B—epilepsy syndrome	3.56e-06	4.26e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—S100B—epilepsy syndrome	3.55e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—APOE—epilepsy syndrome	3.54e-06	4.24e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—POMC—epilepsy syndrome	3.54e-06	4.24e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SOCS3—epilepsy syndrome	3.52e-06	4.22e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SOCS3—epilepsy syndrome	3.52e-06	4.21e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDC42—epilepsy syndrome	3.51e-06	4.21e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDC42—epilepsy syndrome	3.51e-06	4.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT3—epilepsy syndrome	3.5e-06	4.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—S100B—epilepsy syndrome	3.48e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—POMC—epilepsy syndrome	3.48e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KDR—epilepsy syndrome	3.47e-06	4.16e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCL2—epilepsy syndrome	3.46e-06	4.14e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AVP—epilepsy syndrome	3.46e-06	4.14e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SOCS3—epilepsy syndrome	3.45e-06	4.13e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDC42—epilepsy syndrome	3.44e-06	4.12e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—AKT1—epilepsy syndrome	3.42e-06	4.1e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ADAM10—epilepsy syndrome	3.42e-06	4.1e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CCL2—epilepsy syndrome	3.41e-06	4.08e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AVP—epilepsy syndrome	3.4e-06	4.08e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AVP—epilepsy syndrome	3.39e-06	4.07e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CASP3—epilepsy syndrome	3.39e-06	4.06e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PRKCB—epilepsy syndrome	3.34e-06	4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—GPX1—epilepsy syndrome	3.33e-06	3.99e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AVP—epilepsy syndrome	3.33e-06	3.99e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6ST—epilepsy syndrome	3.33e-06	3.99e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—JUN—epilepsy syndrome	3.29e-06	3.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HES1—epilepsy syndrome	3.27e-06	3.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—S100B—epilepsy syndrome	3.24e-06	3.88e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HES1—epilepsy syndrome	3.22e-06	3.85e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HES1—epilepsy syndrome	3.21e-06	3.85e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MMP9—epilepsy syndrome	3.2e-06	3.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SOCS3—epilepsy syndrome	3.2e-06	3.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDC42—epilepsy syndrome	3.2e-06	3.83e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—FYN—epilepsy syndrome	3.18e-06	3.81e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—H2AFX—epilepsy syndrome	3.17e-06	3.8e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MEF2C—epilepsy syndrome	3.16e-06	3.79e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HES1—epilepsy syndrome	3.15e-06	3.77e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—FYN—epilepsy syndrome	3.13e-06	3.75e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—FGF2—epilepsy syndrome	3.13e-06	3.75e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—FYN—epilepsy syndrome	3.12e-06	3.74e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—H2AFX—epilepsy syndrome	3.12e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	3.11e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MEF2C—epilepsy syndrome	3.11e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—H2AFX—epilepsy syndrome	3.11e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—AKT1—epilepsy syndrome	3.11e-06	3.72e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MEF2C—epilepsy syndrome	3.1e-06	3.72e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—BCHE—epilepsy syndrome	3.1e-06	3.72e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AVP—epilepsy syndrome	3.1e-06	3.71e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—FYN—epilepsy syndrome	3.06e-06	3.67e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—YWHAZ—epilepsy syndrome	3.06e-06	3.66e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—H2AFX—epilepsy syndrome	3.05e-06	3.66e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MEF2C—epilepsy syndrome	3.05e-06	3.65e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—POMC—epilepsy syndrome	3.04e-06	3.65e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NGF—epilepsy syndrome	3.02e-06	3.62e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—YWHAZ—epilepsy syndrome	3.01e-06	3.6e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—YWHAZ—epilepsy syndrome	3e-06	3.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCL2—epilepsy syndrome	2.98e-06	3.57e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NGF—epilepsy syndrome	2.97e-06	3.56e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NGF—epilepsy syndrome	2.97e-06	3.56e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	2.96e-06	3.55e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—SRC—epilepsy syndrome	2.95e-06	3.54e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—YWHAZ—epilepsy syndrome	2.94e-06	3.53e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCR5—epilepsy syndrome	2.94e-06	3.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HES1—epilepsy syndrome	2.93e-06	3.51e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	2.93e-06	3.51e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AGT—epilepsy syndrome	2.92e-06	3.5e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TH—epilepsy syndrome	2.92e-06	3.49e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NGF—epilepsy syndrome	2.91e-06	3.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—RELA—epilepsy syndrome	2.9e-06	3.48e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCR5—epilepsy syndrome	2.89e-06	3.47e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCR5—epilepsy syndrome	2.89e-06	3.46e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—VEGFA—epilepsy syndrome	2.88e-06	3.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HTR2A—epilepsy syndrome	2.88e-06	3.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—APOE—epilepsy syndrome	2.86e-06	3.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—FYN—epilepsy syndrome	2.85e-06	3.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MTOR—epilepsy syndrome	2.85e-06	3.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—H2AFX—epilepsy syndrome	2.84e-06	3.4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCR5—epilepsy syndrome	2.83e-06	3.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MEF2C—epilepsy syndrome	2.83e-06	3.39e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HTR2A—epilepsy syndrome	2.82e-06	3.38e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HTR2A—epilepsy syndrome	2.77e-06	3.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	2.74e-06	3.28e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TSC2—epilepsy syndrome	2.73e-06	3.27e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AGT—epilepsy syndrome	2.73e-06	3.27e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NGF—epilepsy syndrome	2.71e-06	3.24e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—FGF2—epilepsy syndrome	2.69e-06	3.22e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TSC2—epilepsy syndrome	2.69e-06	3.22e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AGT—epilepsy syndrome	2.69e-06	3.22e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TSC2—epilepsy syndrome	2.68e-06	3.22e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AGT—epilepsy syndrome	2.68e-06	3.21e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APOE—epilepsy syndrome	2.67e-06	3.2e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—AKT1—epilepsy syndrome	2.64e-06	3.17e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TSC2—epilepsy syndrome	2.63e-06	3.16e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APOE—epilepsy syndrome	2.63e-06	3.15e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCR5—epilepsy syndrome	2.63e-06	3.15e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AGT—epilepsy syndrome	2.63e-06	3.15e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APOE—epilepsy syndrome	2.63e-06	3.15e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KDR—epilepsy syndrome	2.62e-06	3.14e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CASP3—epilepsy syndrome	2.62e-06	3.14e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KDR—epilepsy syndrome	2.58e-06	3.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APOE—epilepsy syndrome	2.58e-06	3.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HTR2A—epilepsy syndrome	2.58e-06	3.09e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KDR—epilepsy syndrome	2.57e-06	3.08e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—JUN—epilepsy syndrome	2.54e-06	3.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KDR—epilepsy syndrome	2.52e-06	3.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PRKCB—epilepsy syndrome	2.52e-06	3.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6ST—epilepsy syndrome	2.51e-06	3.01e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—RELA—epilepsy syndrome	2.5e-06	2.99e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PRKCB—epilepsy syndrome	2.48e-06	2.97e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PRKCB—epilepsy syndrome	2.48e-06	2.97e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MMP9—epilepsy syndrome	2.47e-06	2.96e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6ST—epilepsy syndrome	2.47e-06	2.96e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6ST—epilepsy syndrome	2.47e-06	2.96e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—POMC—epilepsy syndrome	2.46e-06	2.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MTOR—epilepsy syndrome	2.45e-06	2.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TSC2—epilepsy syndrome	2.45e-06	2.93e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AGT—epilepsy syndrome	2.44e-06	2.93e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	2.43e-06	2.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—AKT1—epilepsy syndrome	2.43e-06	2.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PRKCB—epilepsy syndrome	2.43e-06	2.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6ST—epilepsy syndrome	2.42e-06	2.9e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CAT—epilepsy syndrome	2.4e-06	2.88e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—AKT1—epilepsy syndrome	2.4e-06	2.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOE—epilepsy syndrome	2.39e-06	2.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KDR—epilepsy syndrome	2.35e-06	2.81e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	2.34e-06	2.8e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—POMC—epilepsy syndrome	2.3e-06	2.75e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—SRC—epilepsy syndrome	2.28e-06	2.73e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—AKT1—epilepsy syndrome	2.27e-06	2.72e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—POMC—epilepsy syndrome	2.26e-06	2.71e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PRKCB—epilepsy syndrome	2.26e-06	2.71e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—POMC—epilepsy syndrome	2.26e-06	2.7e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CASP3—epilepsy syndrome	2.25e-06	2.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6ST—epilepsy syndrome	2.25e-06	2.69e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCL2—epilepsy syndrome	2.25e-06	2.69e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ALB—epilepsy syndrome	2.24e-06	2.69e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—VEGFA—epilepsy syndrome	2.22e-06	2.66e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—POMC—epilepsy syndrome	2.21e-06	2.65e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCL2—epilepsy syndrome	2.21e-06	2.65e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCL2—epilepsy syndrome	2.21e-06	2.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—JUN—epilepsy syndrome	2.19e-06	2.62e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GPX1—epilepsy syndrome	2.17e-06	2.6e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCL2—epilepsy syndrome	2.17e-06	2.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—epilepsy syndrome	2.13e-06	2.55e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—epilepsy syndrome	2.07e-06	2.47e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—POMC—epilepsy syndrome	2.06e-06	2.46e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—FGF2—epilepsy syndrome	2.03e-06	2.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL2—epilepsy syndrome	2.01e-06	2.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—FGF2—epilepsy syndrome	2e-06	2.4e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—FGF2—epilepsy syndrome	1.99e-06	2.39e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SRC—epilepsy syndrome	1.96e-06	2.35e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—epilepsy syndrome	1.96e-06	2.35e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—FGF2—epilepsy syndrome	1.96e-06	2.35e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—epilepsy syndrome	1.91e-06	2.29e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AGT—epilepsy syndrome	1.9e-06	2.28e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—RELA—epilepsy syndrome	1.89e-06	2.26e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOE—epilepsy syndrome	1.87e-06	2.24e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—RELA—epilepsy syndrome	1.86e-06	2.22e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—RELA—epilepsy syndrome	1.85e-06	2.22e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MTOR—epilepsy syndrome	1.85e-06	2.22e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—epilepsy syndrome	1.84e-06	2.2e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MTOR—epilepsy syndrome	1.82e-06	2.18e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—FGF2—epilepsy syndrome	1.82e-06	2.18e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—RELA—epilepsy syndrome	1.82e-06	2.18e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MTOR—epilepsy syndrome	1.82e-06	2.18e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MTOR—epilepsy syndrome	1.78e-06	2.14e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—epilepsy syndrome	1.72e-06	2.06e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—epilepsy syndrome	1.7e-06	2.04e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—epilepsy syndrome	1.69e-06	2.02e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—RELA—epilepsy syndrome	1.69e-06	2.02e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.69e-06	2.02e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—epilepsy syndrome	1.67e-06	2.01e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—epilepsy syndrome	1.67e-06	2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MTOR—epilepsy syndrome	1.66e-06	1.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—epilepsy syndrome	1.65e-06	1.98e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—JUN—epilepsy syndrome	1.65e-06	1.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—epilepsy syndrome	1.64e-06	1.96e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—JUN—epilepsy syndrome	1.63e-06	1.95e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—JUN—epilepsy syndrome	1.62e-06	1.94e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—epilepsy syndrome	1.61e-06	1.93e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—POMC—epilepsy syndrome	1.6e-06	1.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—JUN—epilepsy syndrome	1.59e-06	1.91e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—epilepsy syndrome	1.58e-06	1.9e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—epilepsy syndrome	1.58e-06	1.89e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—epilepsy syndrome	1.56e-06	1.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—epilepsy syndrome	1.55e-06	1.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	1.54e-06	1.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—epilepsy syndrome	1.53e-06	1.84e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—epilepsy syndrome	1.53e-06	1.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—epilepsy syndrome	1.52e-06	1.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—epilepsy syndrome	1.5e-06	1.8e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SRC—epilepsy syndrome	1.48e-06	1.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JUN—epilepsy syndrome	1.48e-06	1.77e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—epilepsy syndrome	1.46e-06	1.75e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SRC—epilepsy syndrome	1.46e-06	1.75e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SRC—epilepsy syndrome	1.46e-06	1.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—epilepsy syndrome	1.44e-06	1.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—epilepsy syndrome	1.44e-06	1.72e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SRC—epilepsy syndrome	1.43e-06	1.71e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—epilepsy syndrome	1.42e-06	1.7e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—epilepsy syndrome	1.42e-06	1.7e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—epilepsy syndrome	1.42e-06	1.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—epilepsy syndrome	1.4e-06	1.67e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—epilepsy syndrome	1.39e-06	1.67e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SRC—epilepsy syndrome	1.33e-06	1.59e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—epilepsy syndrome	1.29e-06	1.55e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	1.28e-06	1.53e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—epilepsy syndrome	1.22e-06	1.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—epilepsy syndrome	9.86e-07	1.18e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—epilepsy syndrome	9.21e-07	1.1e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—epilepsy syndrome	9.06e-07	1.09e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—epilepsy syndrome	9.04e-07	1.08e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—epilepsy syndrome	8.87e-07	1.06e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—epilepsy syndrome	8.25e-07	9.88e-06	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—epilepsy syndrome	6.43e-07	7.7e-06	CbGpPWpGaD
